
-
Lantheus Holdings NasdaqGM:LNTH Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Location: 201 Burlington Road, Bedford, MA, 01730, United States | Website: https://www.lantheus.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.901B
Cash
938.5M
Avg Qtr Burn
N/A
Short % of Float
12.75%
Insider Ownership
2.29%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RELISTOR Details Constipation | Approved Quarterly sales | |
PYLARIFY (Piflufolastat F 18) Details Prostate cancer, Cancer | Approved Quarterly sales | |
AZEDRA® (iobenguane I 131) Details Pheochromocytoma , Paraganglioma , Solid tumor/s | Approved Quarterly sales | |
DEFINITY® Room Temperature Details Suboptimal echocardiograms | Approved Quarterly sales | |
Flurpiridaz F 18 Details Heart disease, Coronary artery disease | NDA Acceptance for review | |
MK-6240 (florquinitau) Details Alzheimer's disease | NDA Submission | |
¹⁷⁷Lu-PNT2002 Details Cancer, Castration-resistant prostate cancer | Phase 3 Update | |
NAV-4694 (18-flutafuranol) Details Alzheimer's disease | Phase 3 Update | |
1095 (PSMA-targeted iodine-131 labeled small molecule) Details Prostate cancer, Glioblastoma, Cancer | Phase 2 Data readout | |
¹⁷⁷Lu-DOTA-RM2 Details Cancer, Prostate cancer | Phase 1/2 Initiation | |
LNTH-1404 Details Prostate cancer, Cancer | Failed Discontinued |